LDLR and metabolic dysfunction-associated steatohepatitis: The administration of Ac-YVAD-cmk, a caspase-1 inhibitor, can ameliorate insulin resistance, improve liver fibrosis progression, and delay NASH development in male low-density lipoprotein receptor (LDLR) knockout Leiden mice.